可选产品分析
经您允许，我们会使用注重隐私的有限分析来了解哪些研究流程有效。我们不会使用广告跟踪器或会话录制。您可以在偏好设置中更改此选择。请阅读 隐私政策.
Thermo Fisher Scientific Inc.'s published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $240.9B |
|---|
| Revenue (ttm) | 47.4B |
|---|
| Net income (ttm) | 7.1B |
|---|
| EPS (ttm) | $19.0 |
|---|
| Shares out | 369.7M |
|---|
| P/E (trailing) | 37.1x |
|---|
| P/E (forward) | 23.7x |
|---|
| Dividend | $1.88 (0.27%) |
|---|
| Volume | 1,335,395 |
|---|
| Beta | 0.88 |
|---|
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $39.21B | $44.92B | $42.86B | $42.88B | $44.56B | +3.2% |
| Gross profit | $19.63B | $19.01B | $17.56B | $17.73B | $16.78B | -3.9% |
| Operating income | $10.03B | $8.39B | $6.86B | $7.34B | $7.75B | -6.3% |
| Net income | $7.73B | $6.95B | $6.00B | $6.34B | $6.70B | -3.5% |
| EPS (diluted) | $19.46 | $17.63 | $15.45 | $16.53 | $17.74 | -2.3% |
| EBITDA | $11.97B | $11.94B | $6.86B | $11.80B | $11.47B | -1.1% |
| R&D | $1.41B | $1.47B | $1.34B | $1.39B | $1.40B | -0.2% |
| SG&A | $8.01B | $8.99B | $8.45B | $8.60B | $8.73B | +2.2% |
Recent company headlines from major financial publishers.
The Base case represents our modal expectation where Thermo Fisher delivers steady operational execution in line with management guidance. Laboratory Products and Biopharma Services maintains steady recurring demand, while Analytical Instruments sustains moderate single-digit expansion. This path yields our Fair value of $318.21 (implied return of -51.5% at 60.0% probability) versus $656.45 as of $656.45 (as of 2026-09-21). Disconfirmation would appear if customer biopharma spending decelerates below guided ranges or tariff friction erodes gross margin.
In the Bull case, bioprocessing order velocity accelerates swiftly, proprietary analytical instrumentation captures greater market share across Asian and European clinical laboratories, and academic spending rebounds robustly. Under these conditions, valuation expands toward $393.17 representing an expected return of -40.1% at a modeled probability of 20.0%. Confirmation requires consecutive quarters of organic revenue expansion exceeding upper guidance bands and operating margin expansion in analytical tools.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 6.7% | $373 | $392 | $417 | $449 | $491 |
| 7.7% | $330 | $343 | $358 | $377 | $401 |
| 8.7% | $299 | $308 | $318 | $330 | $345 |
| 9.7% | $275 | $281 | $288 | $297 | $307 |
| 10.7% | $255 | $260 | $265 | $271 | $278 |
Upcoming earnings date and setup when available.
每月发布的研究版本所给出的评级。评级比较分析日的价格与公允价值，并不记录判断是否正确。
| 年份 | 1月 | 2月 | 3月 | 4月 | 5月 | 6月 | 7月 | 8月 | 9月 | 10月 | 11月 | 12月 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
